Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8NZ7T
|
|||
| Drug Name |
ACE-1334
|
|||
| Drug Type |
Protein
|
|||
| Indication | Systemic sclerosis [ICD-11: 4A42; ICD-9: 710.1] | Phase 1 | [1] | |
| Company |
Acceleron Pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04948554) A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.